Tectonic Therapeutic (TECX) Common Equity (2017 - 2026)

Tectonic Therapeutic (TECX) has 10 years of Common Equity data on file, last reported at $230.4 million in Q1 2026.

• On a quarterly basis, Common Equity fell 23.46% year-over-year to $230.4 million in Q1 2026; TTM through Mar 2026 was $230.4 million, a 23.46% decrease from a year earlier, with the FY2025 full-year figure at $251.3 million, up 78.53% from the prior year.
• Common Equity for Q1 2026 stood at $230.4 million, down from $251.3 million in the prior quarter.
• Over the last five years, Common Equity for TECX reached as high as $301.0 million in Q1 2025 and fell as low as -$99.6 million in Q1 2024.
• Historically, Common Equity has averaged $100.7 million across 5 years, with a median of $140.8 million in 2024.
• Across the five-year window, Common Equity plunged 181.33% in 2023 and surged 402.32% in 2025, its largest moves.
• Year by year, Common Equity stood at -$45.7 million in 2022, then sank by 85.39% to -$84.6 million in 2023, then soared by 266.33% to $140.8 million in 2024, then soared by 78.53% to $251.3 million in 2025, then retreated by 8.32% to $230.4 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $230.4 million in Q1 2026, $251.3 million in Q4 2025, and $267.5 million in Q3 2025.